Thomas Meredith, MD | |
59 Page Hill Rd, Berlin, NH 03570-3531 | |
(603) 752-2900 | |
(603) 752-3727 |
Full Name | Thomas Meredith |
---|---|
Gender | Male |
Speciality | Pediatrics |
Location | 59 Page Hill Rd, Berlin, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740282680 | NPI | - | NPPES |
30200055 | Medicaid | NH | |
5830418 | Other | AETNA GROUP | |
10489 | Other | NH | STATE LICENSE# |
7111690001 | Other | NH | CIGNA HEALTHCARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208000000X | Pediatrics | 10489 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Thomas Meredith, MD 54 Willow St, Berlin, NH 03570-2084 Ph: (603) 752-3669 | Thomas Meredith, MD 59 Page Hill Rd, Berlin, NH 03570-3531 Ph: (603) 752-2900 |
News Archive
Cynosure, Inc., a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that it has received FDA 510(k) clearance to market its flagship PicoSure Picosecond Laser Workstation for the treatment of acne scars with the FOCUS lens array, the Company's new disposable energy delivery system.
A team of students from Kaunas University of Technology (KTU) BeltaMom has designed a belt for pregnant women that monitors the condition of the fetus from the 2nd trimester.
Nearly half of all Americans will outlive their assets, dying with practically no money at all. Even more worrisome, that's true even among households that met the traditional standards for secure retirement income. ... The results can be measured in more than merely dollars and cents. [MIT Economist James] Poterba's paper found that this group is "disproportionately in poor health," in part because they have no resources to cover medical expenses outside Medicare. Most shocking, many of these households were considered to have entered retirement in good financial shape; they didn't count on outliving their plans (Michael Hiltzik, 7/16).
ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, confirms its JETREA US launch date of Monday January 14th, 2013.
› Verified 2 days ago